1．National Collaborating Centre for Mental Health．Dementia：a NICE-SCIE guideline on supporting people with dementia and their carers in health and social care．Leicester（UK）：The British Psychological Society，2007．

2．Alzheimer’s Association．2015 Alzheimer’s disease facts and figures．Alzheimer’s & Dementia．2015，11（3）：332-384．

3．Goedert M，Spillantini MG．A century of Alzheimer’s disease．Science，2006，314（5800）：777-781．

4．McKhann G，Drachman D，Folstein M，et al．Clinical diagnosis of Alzheimer’s disease：report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease．Neurology，1984，34（7）：939-944．

5．World Health Organisation．The ICD-10 Classification of Mental and Behavioural Disorders．Geneva：World Health Organisation，1993．

6．American Psychiatric Association．Diagnostic and statistical manual of mental disorders，fourth edition，text revision（DSM-Ⅳ-TR）．Washington，DC：American Psychiatric Association，2000．

7．American Psychiatric Association．Diagnostic and statistical manual of mental disorders．fifth edition（DSM-5）．Arlington：American Psychiatric Association，2013．

8．Martin C，Preedy V．Diet and Nutrition in Dementia and Cognitive Decline．Amsterdam：Elsevier，2015．

9．Cerejeira J，Lagarto L，Mukaetova-Ladinska EB．Behavioral and psychological symptoms of dementia．Frontiers in neurology，2012，3：73．

10．Ferri CP，Prince M，Brayne C，et al．Global prevalence of dementia：a Delphi consensus study．Lancet，2005，366（9503）：2112-2117．

11．Prince M，Bryce R，Albanese E，et al．The global prevalence of dementia：A systematic review and meta analysis．Alzheimer’s Dement，2013，9（1）：63-75．

12．Chan KY，Wang W，Wu JJ，et al．Epidemiology of Alzheimer’s disease and other forms of dementia in China，1990-2010：a systematic review and analysis．Lancet，2013，381（9882）：2016-2023．

13．Hebert LE，Weuve J，Scherr PA，et al．Alzheimer disease in the United States（2010-2050）estimated using the 2010 census．Neurology，2013，80（19）：1778-1783．

14．Takizawa C，Thompson PL，van Walsem A，et al．Epidemiological and Economic Burden of Alzheimer’s Disease：A Systematic Literature Review of Data across Europe and the United States of America．J Alzheimers Dis，2015，43（4）：1271-1284．

15．Wimo A，Winblad B，Jönsson L．The worldwide societal costs of dementia：Estimates for 2009．Alzheimer’s & Dementia，2010，6（2）：98-103．

16．田金洲．中国痴呆诊疗指南．北京：人民卫生出版社，2012．

17．Norton S，Matthews FE，Barnes DE，et al．Potential for primary prevention of Alzheimer’s disease：an analysis of population-based data．Lancet Neurology，2014，13（8）：788-794．

18．Reitz C，Mayeux R．Alzheimer disease：epidemiology，diagnostic criteria，risk factors and biomarkers．Biochemical pharmacology，2014，88（4）：640-651．

19．Kumar A，Singh A，Ekavali．A review on Alzheimer’s disease pathophysiology and its management：an update．Pharmacol Rep，2015，67（2）：195-203．

20．Tenreiro S，Eckermann K，Outeiro TF．Protein phosphorylation in neurodegeneration：friend or foe？Frontiers in molecular neuroscience，2014，7：42．

21．Corbett A，Ballard C．New and emerging treatments for Alzheimer’s disease．Expert opinion on emerging drugs，2012，17（2）：147-156．

22．Savva GM，Wharton SB，Ince PG，et al．Age，neuropathology，and dementia．The New England journal of medicine，2009，360（22）：2302-2309．

23．Burns A，Lawlor B，Craig S．Assessment Scales in Old Age Psychiatry，Second Edition．London：Martin Dunitz，2004．

24．Gauthier S，Reisberg B，Zaudig M，et al．International Psychogeriatric Association Expert Conference on mild cognitive impairment．Lancet，2006，367（9518）：1262-1270．

25．Petersen RC，Smith GE，Waring SC，et al．Mild cognitive impairment：clinical characterization and outcome．Archives of neurology，1999，56（3）：303-308．

26．Petersen RC，Negash S．Mild cognitive impairment：an overview．CNS Spectr，2008，13（1）：45-53．

27．Korczyn AD．The underdiagnosis of the vascular contribution to dementia．Journal of the neurological sciences，2005，229：3-6．

28．National Institute for Health and Clinical Excellence（NICE）．NICE technology appraisal guidance 217 - donepezil，galantamine，rivastigmine and memantine for the treatment of Alzheimer’s disease（update）．London：National Institute for Health and Clinical Excellence，2011．

29．Bunn F，Burn AM，Goodman C，et al．Comorbidity and dementia：a scoping review of the literature．BMC medicine，2014，12：192．

30．Anand R，Gill KD，Mahdi AA．Therapeutics of Alzheimer’s disease：Past，present and future．Neuropharmacology，2014，76：27-50．

31．Hyde C，Peters J，Bond M，et al．Evolution of the evidence on the effectiveness and costeffectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer’s disease：systematic review and economic model．Age and ageing，2013，42（1）：14-20．

32．Bond M，Rogers G，Peters J，et al．The effectiveness and cost-effectiveness of donepezil，galantamine，rivastigmine and memantine for the treatment of Alzheimer’s disease（review of Technology Appraisal No．111）：a systematic review and economic model．Health Technol Asses，2012，16（21）：1-470．

33．Alzheimer’s Association．FDA-approved treatments for Alzheimer’s．2007[2016-6]．http://www.alz.org．

34．Qaseem A，Snow V，Cross JT，et al．American College of Physicians/American Academy of Family Physicians Panel on D．Current pharmacologic treatment of dementia：a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians．Annals of Internal Medicine，2008，148（5）：370-378．

35．Qizilbash N，Birks J，López Arrieta J，et al．Tacrine for Alzheimer’s disease．Cochrane Db Syst Rev，1999，（1）：CD000202．

36．Yang GY，Wang YY，Tian JZ，et al．Huperzine A for Alzheimer’s disease：a systematic review and meta-analysis of randomized clinical trials．Plos One，2013，8（9）：e74916．

37．Raschetti R，Albanese E，Vanacore N，et al．Cholinesterase inhibitors in mild cognitive impairment：a systematic review of randomised trials．PLoS Medicine，2007，4（11）：e338．

38．Winblad B，Jones RW，Wirth Y，et al．Memantine in moderate to severe Alzheimer’s disease：a meta-analysis of randomised clinical trials．Dement Geriatr Cogn Disord，2007，24（1）：20-27．

39．Yang Z，Zhou X，Zhang Q．Effectiveness and safety of memantine treatment for Alzheimer’s disease．J Alzheimers Dis，2013，36（3）：445-458．

40．Matsunaga S，Kishi T，Iwata N．Combination therapy with cholinesterase inhibitors and memantine for Alzheimer’s disease：a systematic review and meta-analysis．Int J Neuropsychopharmacol，2015，18（5）：pyu115．

41．田金洲．中国痴呆诊疗指南．北京：人民卫生出版社，2012．

42．Winblad B．Piracetam：a review of pharmacological properties and clinical uses．CNS Drug Reviews，2005，11（2）：169-182．

43．Malykh AG，Sadaie MR．Piracetam and piracetam-like drugs：from basic science to novel clinical applications to CNS disorders．Drugs，2010，70（3）：287-312．

44．Waegemans T，Wilsher CR，Danniau A，et al．Clinical efficacy of piracetam in cognitive impairment：a meta-analysis．Dement Geriatr Cogn Disord，2002，13（4）：217-224．

45．Flicker L，Grimley Evans G．Piracetam for dementia or cognitive impairment．Cochrane Database of Systematic Reviews，2004，（2）：CD001011．

46．Herrmann WM，Stephan K，Gaede K，et al．A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia．Dement Geriatr Cogn，1997，8（1）：9-17．

47．Saletu B，Paulus E，Linzmayer L，et al．Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia：a double-blind，placebo-controlled，clinical and EEG/ERP mapping study．Psychopharmacology，1995，117（4）：385-395．

48．Saletu B，Garg A，Shoeb A．Safety of nicergoline as an agent for management of cognitive function disorders．Biomed Res Int，2014，（2014）：ID 610103．

49．Fioravanti M，Flicker L．Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment．Cochrane Database of Systematic Reviews，2001，（4）：CD003159．

50．Winblad B，Fioravanti M，Dolezal T，et al．Therapeutic use of Nicergoline．Clin Drug Invest，2008，28（9）：533-552．

51．Olin J，Schneider L，Novit A，et al．Hydergine for dementia．Cochrane Database of Systematic Reviews，2001，（2）：CD000359．

52．Lei X，Yu J，Niu Q，et al．The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer’s disease amyloid-beta peptides．Scientific Reports，2015，5：16541．

53．Lopez-Arrieta JM，Birks J．Nimodipine for primary degenerative，mixed and vascular dementia．Cochrane Database of Systematic Reviews，2002，（3）：CD000147．

54．Alvarez-Sabin J，Roman GC．Citicoline in vascular cognitive impairment and vascular dementia after stroke．Stroke，2011；42（1 Suppl）：S40-43．

55．Grieb P．Neuroprotective properties of citicoline：facts，doubts and unresolved issues．CNS Drugs，2014，28（3）：185-193．

56．Overgaard K．The effects of citicoline on acute ischemic stroke：a review．Journal of Stroke and Cerebrovascular Diseases，2014，23（7）：1764-1769．

57．Gareri P，Castagna A，Cotroneo AM，et al．The role of citicoline in cognitive impairment：pharmacological characteristics，possible advantages，and doubts for an old drug with new perspectives．Clinical Interventions in Aging，2015，10：1421-1429．

58．Evans JG，Wilcock G，Birks J．Evidence-based pharmacotherapy of Alzheimer’s disease．The International Journal of Neuropsychopharmacology，2004，7（3）：351-369．

59．Birks J，Grimley-Evans J．Ginkgo biloba for cognitive impairment and dementia．Cochrane Db Syst Rev，2009，（1）：CD003120．

60．Gauthier S，Schlaefke S．Efficacy and tolerability of Ginkgo biloba extract EGb 761（R）in dementia：a systematic review and meta-analysis of randomized placebo-controlled trials．Clinical Interventions in Aging，2014，9：2065-2077．

61．Jiang L，Su L，Cui H，et al．Ginkgo biloba extract for dementia：a systematic review．Shanghai Archives of Psychiatry，2013，25（1）：10-21．

62．Tan MS，Yu JT，Tan CC，et al．Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia：a systematic review and meta-analysis．J Alzheimers Dis，2015，43（2）：589-603．

63．Ihl R，Bachinskaya N，Korczyn AD，et al．Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features：a randomized controlled trial．Int J Geriatr Psych，2011，26（11）：1186-1194．

64．Ihl R，Bunevicius R，Frolich L，et al．World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care．Int J Psychiatry Clin Pract，2015，19（1）：2-7．

65．Allain H，Bentue-Ferrer D．Clinical efficacy of almitrine-raubasine．an overview．European Neurology，1998，39（Suppl．1）：39-44．

66．Li SW，Long J，Ma ZZ，et al．Assessment of the therapeutic activity of a combination of almitrine and raubasine on functional rehabilitation following ischaemic stroke．Current Medical Research and Opinion，2004，20（3）：409-415．

67．Yang W，Liu M，Teng J，et al．Almitrine-Raubasine combination for dementia．Cochrane Database of Systematic Rreviews，2011，（3）：CD008068．

68．Hindmarch I，Coleston DM，Kerr JS．Psychopharmacological effects of pyritinol in normal volunteers．Neuropsychobiology，1990，24（3）：159-164．

69．Heiss WD，Kessler J，Mielke R，et al．Long-term effects of phosphatidylserine，pyritinol，and cognitive training in Alzheimer’s disease．A neuropsychological，EEG，and PET investigation．Dementia，1994，5（2）：88-98．

70．Fischhof PK，Saletu B，Ruther E，et al．Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type（SDAT）and multi-infarct dementia（MID）．Neuropsychobiology，1992，26（1-2）：65-70．

71．Sampson EL，Jenagaratnam L，McShane R．Metal protein attenuating compounds for the treatment of Alzheimer’s dementia．Cochrane Database of Systematic Reviews，2014，（2）：CD005380．

72．Lambracht-Washington D，Rosenberg RN．Advances in the development of vaccines for Alzheimer’s disease．Discovery Medicine，2013，15（84）：319-326．

73．Sevigny J，Chiao P，Bussiere T，et al．The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease．Nature，2016，537（7618）：50-56．

74．Dysken MW，Sano M，Asthana S，et al．Effect of vitamin E and memantine on functional decline in Alzheimer disease：the TEAM-AD VA cooperative randomized trial．JAMA，2014，311（1）：33-44．

75．Farina N，Isaac MGEN，Clark AR，et al．Vitamin E for Alzheimer’s dementia and mild cognitive impairment．Cochrane Database of Systematic Reviews，2012，（11）：CD002854．

76．La Fata G，Weber P，Mohajeri MH．Effects of vitamin E on cognitive performance during ageing and in Alzheimer’s disease．Nutrients，2014，6（12）：5453-5472．

77．Rijpma A，Meulenbroek O，Rikkert MGMO．Cholinesterase inhibitors and add-on nutritional supplements in Alzheimer’s disease A systematic review of randomized controlled trials．Ageing Res Rev，2014，16：105-112．

78．Malouf R，Grimley Evans J．Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people．Cochrane Database of Systematic Reviews，2008，（4）：CD004514．

79．Li MM，Yu JT，Wang HF，et al．Efficacy of vitamins B supplementation on mild cognitive impairment and Alzheimer’s disease：a systematic review and meta-analysis．Current Alzheimer research，2014，11（9）：844-852．

80．Apetz N，Munch G，Govindaraghavan S，et al．Natural compounds and plant extracts as therapeutics against chronic inflammation in Alzheimer’s Disease—a translational perspective．CNS Neurol Disord Drug Targets，2014，13（7）：1175-1191．

81．Babri S，Mohaddes G，Feizi I，et al．Effect of troxerutin on synaptic plasticity of hippocampal dentate gyrus neurons in a beta-amyloid model of Alzheimers disease：an electrophysiological study．European Journal of Pharmacology，2014，732：19-25．

82．Hugel H．Brain Food for Alzheimer-Free Ageing：Focus on Herbal Medicines．In：Vassallo N，editor．Natural Compounds as Therapeutic Agents for Amyloidogenic Diseases．Switzerland：Springer International Publishing，2015．

83．Venigalla M，Sonego S，Gyengesi E，et al．Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer’s disease．Neurochemistry International，2016，95：63-74．

84．Cox KH，Pipingas A，Scholey AB．Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population．Journal of Psychopharmacology，2015，29（5）：642-651．

85．Crichton GE，Bryan J，Murphy KJ．Dietary antioxidants，cognitive function and dementia—a systematic review．Plant Foods Hum Nutr，2013，68（3）：279-292．

86．Rafnsson SB，Dilis V，Trichopoulou A．Antioxidant nutrients and age-related cognitive decline：a systematic review of population-based cohort studies．Eur J Nutr，2013，52（6）：1553-1567．

87．Sachdeva A，Kumar K，Anand KS．Non pharmacological cognitive enhancers—current perspectives．Journal of Clinical and Diagnostic Rresearch，2015，9（7）：VE01-VE06．

88．Brett L，Traynor V，Stapley P．Effects of physical exercise on health and well-being of individuals living with a dementia in nursing homes：a systematic review．Journal of the American Medical Directors Association，2016，17（2）：104-116．

89．Livingston G，Kelly L，Lewis-Holmes E，et al．Non-pharmacological interventions for agitation in dementia：systematic review of randomised controlled trials．The British Journal of Psychiatry，2014，205（6）：436-442．

90．Orgeta V，Qazi A，Spector AE，et al．Psychological treatments for depression and anxiety in dementia and mild cognitive impairment．Cochrane Database of Systematic Reviews，2014，1：CD009125．

91．Cortes F，Nourhashemi F，Guerin O，et al．Prognosis of Alzheimer’s disease today：A twoyear prospective study in 686 patients from the REAL-FR Study．Alzheimers Dement，2008，4（1）：22-29．

92．Gillette-Guyonnet S，Andrieu S，Nourhashemi F，et al．Long-term progression of Alzheimer’s disease in patients under antidementia drugs．Alzheimers Dement，2011，7（6）：579-592．

93．Brookmeyer R，Corrada MM，Curriero FC，et al．Survival following a diagnosis of Alzheimer disease．Archives of Neurology，2002，59（11）：1764-1767．

94．Zanetti O，Solerte SB，Cantoni F．Life expectancy in Alzheimer’s disease（Ad）．Arch Gerontol Geriat，2009，49：237-243．

95．Kelly AM．Non-pharmacological approaches to cognitive enhancement．Handbook of Experimental Pharmacology，2015，228：417-439．

96．Zhong G，Wang Y，Zhang Y，et al．Smoking is associated with an increased risk of dementia：a meta-analysis of prospective cohort studies with investigation of potential effect modifiers．Plos One，2015，10（4）：e0126169．

97．Beydoun MA，Beydoun HA，Gamaldo AA，et al．Epidemiologic studies of modifiable factors associated with cognition and dementia：systematic review and meta-analysis．BMC Public Health，2014，14：643．

98．McGuinness B，Craig D，Bullock R，et al．Statins for the prevention of dementia．Cochrane Database of Systematic Reviews，2016，（1）：CD003160．

99．Beishon LC，Harrison JK，Harwood RH，et al．The evidence for treating hypertension in older people with dementia：a systematic review．Journal of Human Hypertension，2014，28（5）：283-287．

100．Rouch L，Cestac P，Hanon O，et al．Antihypertensive drugs，prevention of cognitive decline and dementia：a systematic review of observational studies，randomized controlled trials and meta-analyses，with discussion of potential mechanisms．CNS Drugs，2015，29（2）：113-130．

101．Wang J，Tan L，Wang HF，et al．Anti-inflammatory drugs and risk of Alzheimer’s disease：an updated systematic review and meta-analysis．J Alzheimers Dis，2015，44（2）：385-396．

102．Sydenham E，Dangour AD，Lim WS．Omega 3 fatty acid for the prevention of cognitive decline and dementia．Cochrane Database of Systematic Reviews，2012，（6）：CD005379．

103．Forbes SC，Holroyd-Leduc JM，Poulin MJ，et al．Effect of nutrients，dietary supplements and vitamins on cognition：a systematic review and meta-analysis of randomized controlled trials．Canadian Geriatrics Journal，2015，18（4）：231-245．

104．Mohajeri MH，Troesch B，Weber P．Inadequate supply of vitamins and DHA in the elderly：implications for brain aging and Alzheimer-type dementia．Nutrition，2015，31（2）：261-275．

105．Loef M，Walach H．Fruit，vegetables and prevention of cognitive decline or dementia：a systematic review of cohort studies．The Journal of Nutrition，Health & Aging，2012，16（7）：626-630．

106．Solfrizzi V，Panza F，Frisardi V，et al．Diet and Alzheimer’s disease risk factors or prevention：the current evidence．Expert Review of Neurotherapeutics，2011，11（5）：677-708．

107．Mosconi L，Murray J，Tsui WH，et al．Mediterranean diet and magnetic resonance imagingassessed brain atrophy in cognitively normal individuals at risk for Alzheimer’s disease．The Journal of Prevention of Alzheimer’s Disease，2014，1（1）：23-32．

108．Berti V，Murray J，Davies M，et al．Nutrient patterns and brain biomarkers of Alzheimer’s disease in cognitively normal individuals．The Journal of Nutrition，Health & Aging，2015，19（4）：413-423．

109．Wu S，Ding Y，Wu F，et al．Omega-3 fatty acids intake and risks of dementia and Alzheimer’s disease：a meta-analysis．Neuroscience and Biobehavioral Reviews，2015，48：1-9．

110．Rondanelli M，Faliva MA，Peroni G，et al．Focus on pivotal role of dietary intake（Diet and Supplement）and blood levels of tocopherols and tocotrienols in obtaining successful aging．International Journal of Molecular Sciences，2015，16（10）：23227-23249．

111．Barnard ND，Bush AI，Ceccarelli A，et al．Dietary and lifestyle guidelines for the prevention of Alzheimer’s disease．Neurobiol Aging，2014，35：S74-S78．

112．赵斌，蔡志友．阿尔茨海默病．北京：科学出版社，2015．